Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Development of a Nomogram for Predicting High-grade Prostate Cancer on Biopsy: the Significance of Serum Testosterone Levels

HISAMITSU IDE, MITSUKO YASUDA, KOJIRO NISHIO, KEISUKE SAITO, SHUJI ISOTANI, YUTAKA KAMIYAMA, SATORU MUTO and SHIGEO HORIE
Anticancer Research July 2008, 28 (4C) 2487-2492;
HISAMITSU IDE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MITSUKO YASUDA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KOJIRO NISHIO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KEISUKE SAITO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SHUJI ISOTANI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YUTAKA KAMIYAMA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SATORU MUTO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SHIGEO HORIE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: shorie@med.teikyo-u.ac.jp
  • Article
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 28 no. 4C 2487-2492
PubMed 
18751439

Published By 
International Institute of Anticancer Research
Print ISSN 
0250-7005
Online ISSN 
1791-7530
History 
  • Received December 27, 2007
  • Revision received May 19, 2008
  • Accepted May 26, 2008
  • Published online July 1, 2008.

Copyright & Usage 
Copyright© 2008 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved

Author Information

  1. HISAMITSU IDE,
  2. MITSUKO YASUDA,
  3. KOJIRO NISHIO,
  4. KEISUKE SAITO,
  5. SHUJI ISOTANI,
  6. YUTAKA KAMIYAMA,
  7. SATORU MUTO and
  8. SHIGEO HORIE
  1. Department of Urology, Teikyo University School of Medicine, Itabashi-ku, Tokyo, Japan
  1. Correspondence to: Shigeo Horie, MD, Department of Urology, Teikyo University School of Medicine, 2-11-1, Kaga, 2chome, Itabashi-ku, Tokyo 173-8605, Japan. Tel: +81 3 3964 2497, Fax: +81 3 3964 8934, e-mail: shorie{at}med.teikyo-u.ac.jp

Statistics from Altmetric.com

Cited By...

  • 35 Citations
  • Citations
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

PreviousNext
Back to top

In this issue

Anticancer Research: 28 (4C)
Anticancer Research
Vol. 28, Issue 4C
July-August 2008
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Development of a Nomogram for Predicting High-grade Prostate Cancer on Biopsy: the Significance of Serum Testosterone Levels
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
9 + 6 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Development of a Nomogram for Predicting High-grade Prostate Cancer on Biopsy: the Significance of Serum Testosterone Levels
HISAMITSU IDE, MITSUKO YASUDA, KOJIRO NISHIO, KEISUKE SAITO, SHUJI ISOTANI, YUTAKA KAMIYAMA, SATORU MUTO, SHIGEO HORIE
Anticancer Research Jul 2008, 28 (4C) 2487-2492;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Development of a Nomogram for Predicting High-grade Prostate Cancer on Biopsy: the Significance of Serum Testosterone Levels
HISAMITSU IDE, MITSUKO YASUDA, KOJIRO NISHIO, KEISUKE SAITO, SHUJI ISOTANI, YUTAKA KAMIYAMA, SATORU MUTO, SHIGEO HORIE
Anticancer Research Jul 2008, 28 (4C) 2487-2492;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • The FSHR Expression in Head and Neck Squamous Cell Cancer. A Pilot Immunohistochemical Study
  • Low Serum Testosterone But Not Obesity Predicts High Gleason Score at Biopsy Diagnosed as Prostate Cancer in Patients with Serum PSA Lower than 20 ng/ml
  • Along the Pituitary-Testis-Prostate Axis, Serum Total Testosterone Is a Significant Preoperative Variable Independently Contributing to Separating the Prostate Cancer Population into Prostatectomy Gleason Score Groups
  • Investigative Clinical Study on Prostate Cancer Part IX and X: Estradiol and the Pituitary-Testicular-Prostate Axis at the Time of Initial Diagnosis and Subsequent Cluster Selection of the Patient Population after Radical Prostatectomy
  • Serum Sex Steroids Depict a Nonlinear U-Shaped Association with High-Risk Prostate Cancer at Radical Prostatectomy
  • Investigative Clinical Study on Prostate Cancer Part VIII: Prolactin Hormone and the Pituitary-Testicular-Prostate Axis at the Time of Initial Diagnosis and Subsequent Cluster Selection of the Patient Population after Radical Prostatectomy
  • Investigative Clinical Study on Prostate Cancer Part VII: Prolactin and the Pituitary-Testis-Prostate Axis at the Time of Initial Diagnosis and Subsequent Cluster Selection of the Patient Population
  • Lower Serum Total Testosterone is Associated with Lymph Node Metastases in a Radical Prostatectomy Cohort Study
  • Investigative Clinical Study on Prostate Cancer Part V: Luteinizing Hormone and the Pituitary-Testicular-Prostate Axis at the Time of Initial Diagnosis and Subsequent Cluster Selection of the Patient Population
  • Google Scholar

More in this TOC Section

  • Efficacy of Pembrolizumab as Second or Third-line Therapy for Local Advanced and Metastatic Urothelial Cancer
  • End-of-life Androgen Deprivation Syndrome With Enzalutamide in Metastatic Prostate Cancer: A Case Report
  • Effect of a Biweekly Dosing Schedule on Severe Neutropenia Induced by Trifluridine/Tipiracil in Colorectal Cancer
Show more Clinical Studies

Similar Articles

Anticancer Research

© 2025 Anticancer Research

Powered by HighWire